Want to see SE:ATORX full AI Analyst Report?
ATORX Stock Chart & Stats
kr0.03
>-kr0.01(-8.19%)
At close: 4:00 PM EDT
kr0.03
>-kr0.01(-8.19%)
Day’s Range― - ―
52-Week Rangekr0.01 - kr0.57
Previous CloseN/A
Volume25.04M
Average Volume (3M)15.91M
Market Cap
kr41.39M
Enterprise Valuekr122.60M
Total Cash (Recent Filing)kr16.61M
Total Debt (Recent Filing)kr29.93M
Price to Earnings (P/E)―
Beta0.87
Next Earnings
Oct 22, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.06
Shares Outstanding3,568,107,000
10 Day Avg. Volume27,707,993
30 Day Avg. Volume15,907,115
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.35
Price to Sales (P/S)18.04
P/FCF Ratio-0.06
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.19
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improved LeverageThe sharp reduction in debt-to-equity indicates that recapitalization and/or debt reduction has improved the company’s capital structure. Lower leverage can reduce balance-sheet pressure and interest-related constraints, giving management more flexibility while clinical programs continue to develop.
Free Cash Flow ImprovementImprovement in free cash flow from the prior year suggests some progress in controlling or absorbing cash requirements, even though funding needs remain substantial. If sustained, this trend could extend the operating runway and reduce the pace of external financing required.
Reduced Net LossA smaller net loss year over year provides evidence of some improvement in reported earnings performance. Although profitability remains far away and the company is still pre-commercial, continued loss reduction could support more efficient development spending over the medium term.
Bears Say
Minimal And Declining RevenueMinimal and declining revenue shows that Alligator Bioscience has not yet established meaningful commercial scale. This leaves the company dependent on future partnering, milestones, or financing rather than recurring product revenue, making progress highly dependent on pipeline development.
Persistent Cash BurnDeeply negative operating and free cash flow indicate that ongoing research and development consumes substantial cash without internally funding operations. The resulting need for significant external funding can constrain strategic choices and expose the company to repeated financing requirements.
Thin Equity BaseA very thin equity base leaves limited balance-sheet capacity to absorb continued losses or support development spending. Combined with a very large negative return on equity and declining total assets, this weakens financial flexibility during the clinical development period.
Alligator Bioscience AB News
ATORX FAQ
What was Alligator Bioscience AB’s price range in the past 12 months?
Alligator Bioscience AB lowest stock price was kr0.01 and its highest was kr0.57 in the past 12 months.
What is Alligator Bioscience AB’s market cap?
Alligator Bioscience AB’s market cap is kr41.39M.
When is Alligator Bioscience AB’s upcoming earnings report date?
Alligator Bioscience AB’s upcoming earnings report date is Oct 22, 2026 which is yesterday.
How were Alligator Bioscience AB’s earnings last quarter?
Alligator Bioscience AB released its earnings results on Aug 26, 2026. The company reported -kr0.041 earnings per share for the quarter.
Is Alligator Bioscience AB overvalued?
According to Wall Street analysts Alligator Bioscience AB’s price is currently Overvalued.
Does Alligator Bioscience AB pay dividends?
Alligator Bioscience AB does not currently pay dividends.
What is Alligator Bioscience AB’s EPS estimate?
Alligator Bioscience AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Alligator Bioscience AB have?
Alligator Bioscience AB has 3,568,107,000 shares outstanding.
What happened to Alligator Bioscience AB’s price movement after its last earnings report?
Alligator Bioscience AB reported an EPS of -kr0.041 in its last earnings report. Following the earnings report the stock price went up 21.053%.
Which hedge fund is a major shareholder of Alligator Bioscience AB?
Currently, no hedge funds are holding shares in SE:ATORX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Alligator Bioscience AB
Alligator Bioscience AB (publ) is a research-intensive biotechnology company based in Lund, Sweden, focused on developing innovative antibody-based treatments for cancer. The company leverages several proprietary technology platforms to drive its drug development. These include ALLIGATOR-GOLD and ALLIGATOR-FAB, an extensive human antibody library boasting roughly 60 billion distinct antibody fragments; FIND, a molecular evolution technique used for optimizing antibodies and other proteins; and RUBY, a specialized format for creating bispecific antibodies. Alligator Bioscience's pipeline features several promising candidates. In the clinical stage, Mitazalimab, an immunostimulatory CD40 antibody, has successfully completed Phase I trials for metastatic cancer. Also undergoing Phase I clinical evaluation is ATOR-1017, another immunostimulatory antibody designed to bind to the 4-1BB receptor on tumor-specific T cells. For its preclinical efforts, the company is advancing ALG.APV-527, a bispecific antibody targeting both 4-1BB and 5T4 for cancer therapy. Additionally, Alligator Bioscience holds an interest in the Biosynergy (AC101) project, which is currently in Phase I. To bolster its research and development capabilities, Alligator Bioscience has formed multiple strategic collaborations. It has a co-development partnership with Aptevo Therapeutics Inc. for ALG.APV-527, and a research alliance with MacroGenics, Inc. to create novel immunotherapies. Further collaborations include a joint research agreement with BioArctic AB (publ) to utilize proprietary antibody generation technologies for new product candidates, and a research and license agreement with Orion Corporation aimed at discovering and developing new bispecific antibody cancer therapeutics. The company was established in 2000.
Technical Analysis
BioInvent International AB
―
Oncopeptides AB
―
Elicera Therapeutics AB
―
Immunicum AB
―
Cantargia AB
―